The circadian melatonin rhythm and its modulation: Possible impact on hypertension

Journal of Hypertension

Volumn 27, Issue SUPPL. 6, 2009, Pages

  Reiter, Russel J ^a   Tan, Dan Xian ^a   Korkmaz, Ahmet ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Blood pressure; Circadian disruption; Hypertension; Melatonin

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MELATONIN; PLACEBO; VACCINE; VASODILATOR AGENT; VIPER VENOM;

ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DESIGN; DRUG EFFICACY; ESSENTIAL HYPERTENSION; EVENING DOSAGE; HUMAN; HYPERTENSION; LIGHT DARK CYCLE; NIGHT; NIGHT SLEEP; NONHUMAN; PHOTOPERIODICITY; PINEAL BODY; PRIORITY JOURNAL; REVIEW; RODENT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; URINE;

EID: 68249122123     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000358832.41181.bf     Document Type: Review

References (24)

1. Zanoboni A, Zanoboni-Muciaccia W. Experimental hypertension in pinealectomized rats. Life Sci 1967; 6:2327-2331.
2. Holmes SW, Sugden D. The effect of melatonin on pinealectomy-induced hypertension in the rat. Br J Pharmacol 1976; 56:360-361.
3. Hisada T, Ozono S, Sato K, Watanabe Y, Watanabe M. Relationship between metabolic rhythm in the pineal body and the systemic blood pressure. IRCS J Med Sci 1976; 4:142-143.
4. Karppanen H, Airaksinen MM, Särkimäki I. Effects in rats of pinealectomy and oxypertine on spontaneous locomotor activity and blood pressure during various light schedules. Am Med Exp Fenn 1973; 51:93-103.
5. Karppanen H, Vapaatalo H. Effects of an aldosterone antagonist, spironolactone on pinealectomized rats. Pharmacology 1971; 3:76-84.
6. Reiter RJ. Melatonin: The chemical expression of darkness. Mol Cell Endocrinol 1991; C153-C158.
7. Brainard GC, Lewy AJ, Menaker M, Fredericksin RH, Miller LS, Weleber RG, et al. Dose-response relationship between light irradiance and suppression of melatonin in human volunteers. Brain Res 1988; 454:213-218. (Pubitemid 18159790)
8. Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab 1991; 73:1276-1280.
9. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science 1980; 210:1267-1269.
10. Reiter RJ, Tan DX, Korkmaz A, Erren TC, Piekarski C, Tamura H, Manchester LC. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncogen 2007; 13:303-328. (Pubitemid 351655045)
11. Erren TC, Pape HG, Reiter RJ, Piekarski C. Chronodisruption and cancer. Naturwissenschaften 2008; 95:367-382.
12. Simko F, Paulis L Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42:319-322. (Pubitemid 46581667)
13. Simko F, Paulis L Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 2007; 56:671-684.
14. O'Brien E, Scheridan J, O'Malley K. Dippers and non-dippers. Lancet 1988; 2:397.
15. Mansoor GA. Sleep artigraphy in hypertensive patients with the "nondipper" blood pressure prolife. J Hum Hypertens 2002; 16:237-242.
16. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Relation between nocturnal decline in blood pressure and mortality: the Ohasama study. Am J Hypertens 1997; 10:1201-1207. (Pubitemid 28005341)
17. Rizzoni D, Muiesan ML, Montani G, Zulli R, Calebich S, Agabiti-Rosei E. Relationship between initial cardiovascular structural changes and daytime and night-time blood pressure monitoring. Am J Hypertens 1992; 5:180-186.
18. Shimada K, Kawamoto I, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T. Diurnal blood variation and silent cardiovascular damage in elderly patients with hypertension. J Hypertens 1992; 10:875-878.
19. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801. (Pubitemid 24363980)
20. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003; 12:19-24. (Pubitemid 36416949)
21. Scheer FAJL, van Montfrans GA, Van Someren EJW, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43:192-197. (Pubitemid 38174173)
22. Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005; 18:1614-1618. (Pubitemid 41814684)
23. Scheer FAJL. Potential use of melatonin as adjunct antihypertensive therapy. Am J Hypertens 2005; 18:1619-1620.
24. Liebowitz A, Peleg E, Sharabi Y, Shabatai Z, Shamiss A, Grossman E. The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. Am J Hypertens 2008; 21:348-351. (Pubitemid 351323274)